Metfirst XL 25 Tablet contains Metoprolol Succinate 25 mg, a beta-1 selective adrenergic receptor blocker primarily used in the management of cardiovascular conditions. This medication is indicated for the treatment of hypertension, angina pectoris, and heart failure, as well as for the prevention of myocardial infarction. Metoprolol Succinate works by selectively blocking beta-1 receptors in the heart, leading to a decrease in heart rate, myocardial contractility, and cardiac output, thereby reducing blood pressure and oxygen demand of the heart muscle. The extended-release formulation of Metfirst XL 25 ensures a consistent plasma concentration, allowing once-daily dosing and improved patient compliance. It is contraindicated in patients with severe bradycardia, cardiogenic shock, decompensated heart failure, and certain conduction disorders. Caution is advised in individuals with asthma, diabetes, or peripheral vascular disease. Common adverse effects may include fatigue, dizziness, hypotension, and gastrointestinal disturbances. Dose adjustments may be necessary in renal or hepatic impairment. Patients should not abruptly discontinue therapy to avoid exacerbation of angina or precipitating myocardial infarction. Metfirst XL 25 should be used under medical supervision with regular monitoring of blood pressure, heart rate, and clinical status to optimize therapeutic outcomes.